Kala Bio Inc(KALA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -73.93 | Insider Own | 3.89% | Shs Outstand | 19.3M | Perf Week | -5.71% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 18.6M | Perf Month | -64.26% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 3.63% | Short Float | 2.9% | Perf Quarter | -75.35% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 9.19% | Short Ratio | 0.36 | Perf Half Y | -96.71% |
| Sales | 0.00B | P/B | 0.38 | EPS next 5Y | - | ROA | -43.23% | Short Interest | 0.54M | Perf YTD | -99.35% |
| Book/sh | 0.47 | P/C | 0.48 | EPS past 3/5Y | 51.75% 49.38% | ROE | -345.32% | 52W High | -99.81% ($95.50) | Perf Year | -99.57% |
| Cash/sh | 0.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -111.46% | 52W Low | 56.98% ($0.11) | Perf 3Y | -99.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 78.25% | Gross Margin | - | Volatility(W/M) | 7.84% 17.69% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.88 | EPS Q/Q | 75.1% | Profit Margin | - | RSI (14) | 22.03 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.88 | Sales Q/Q | - | SMA20 | -29.2% ($0.25) | Beta | -2.31 | Target Price | $1250 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -61.58% ($0.47) | Rel Volume | 0.07 | Prev Close | $0.18 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -0.39% - | SMA200 | -97.47% ($7.11) | Avg Volume(3M) | 1.49M | Price | $0.18 |
| IPO | 2017/7/20 | Option/Short | No/Yes | Trades | 283 | Volume | 109,703 | Change | 2.33% |
Originally a biotech built around mesenchymal stem cell secretome (MSC-S) therapies for ophthalmic diseases, the company is now an clinical-stage/transitioning biotech pivoting toward an AI bio platform and strategic restructuring following the clinical failure of its lead pipeline candidate, KPI-012.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
KALA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #553 of 594 in the industry
Based on market cap of $3M.
FAQ
What kind of company is KALA?
KALA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KALA?
The market cap of KALA is approximately $3M, ranking 5,701 within its sector.
What is the 52-week high and low for KALA?
KALA has recorded a 52-week high of $95.50 and a low of $0.11.
